Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on June 15, 2015. The report addresses a material modification to the rights of security holders regarding the company's capital structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action rather than financial performance.
Material Changes
- Authorized Share Increase: On June 15, 2015, the Company filed an amendment to its Second Amended and Restated Articles of Incorporation.
- Share Count Adjustment: The number of authorized shares of common stock (par value $0.00001) was increased from 20,000,000 to 40,000,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the Certificate of Incorporation.
Key Facts for Investor Verification
- Verify the effective date of the share authorization increase (June 15, 2015).
- Confirm the new total authorized common stock count is 40,000,000 shares.
- Review the filed Certificate of Amendment (Exhibit 3.2) for any additional terms or conditions not summarized here.